You usually cannot get a familial Alzheimer's genetic panel on your own terms before a memory clinic visit, and in most cases you should not try. The three-gene panel (APP, PSEN1, PSEN2) explains only a small slice of Alzheimer's disease, insurers gate it behind a documented family pedigree and genetic counseling, and the National Institute on Aging says genetic testing is not routinely used in clinical settings to diagnose or predict dementia risk at all. That does not make the question pointless. If someone in your family carries a known APP, PSEN1 or PSEN2 variant, or your relatives developed dementia in their forties and fifties across multiple generations, there is a real clinical pathway — and the useful work before a clinic visit is gathering the pedigree, asking for a referral to a clinic with genetic counseling on site, and understanding what testing would and would not protect you from.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What a familial Alzheimer's panel actually tests for
- Why the memory clinic may decline to order it
- Coverage: what insurers will and will not pay for
- What it costs if you pay yourself
- GINA protects less than most people assume
- How to ask for the right referral
- Frequently Asked Questions
What a familial Alzheimer's panel actually tests for
"Familial Alzheimer's disease" in the strict genetic sense means autosomal dominant inheritance: a single copy of a pathogenic variant in APP, PSEN1 or PSEN2 causes the disease, and each child of a carrier has a 50% chance of inheriting it. These are the three genes a familial panel targets. That pattern is rare. According to the National Institute on Aging's Alzheimer's disease genetics fact sheet, fewer than 10% of Alzheimer's cases begin before age 65, and only 10–15% of those early-onset cases trace to variants in those three genes. Multiply that out and a panel-detectable cause accounts for roughly one in a hundred cases or fewer.
The practical consequence: most people with a family history of Alzheimer's — including people with a parent who had it in their seventies — will get a negative panel result that changes nothing about their risk. A negative result does not mean low risk. It means the specific autosomal dominant causes were not found. APOE testing is a separate thing and frequently confused with it. APOE ε4 is a risk-modifying variant, not a cause, and it is not on an autosomal dominant panel.
Why the memory clinic may decline to order it
The strongest reason is that it is not standard care. The NIA states directly that genetic tests are not routinely used clinically to diagnose or predict Alzheimer's risk, which is why a first visit may focus on cognitive testing, imaging and bloodwork rather than genetics. Professional guidance says the same.
The 2011 ACMG/NSGC joint practice guideline, reaffirmed in 2018 and reclassified as a Practice Resource, recommends against clinical APOE testing for risk prediction. For autosomal dominant Alzheimer's, it recommends that presymptomatic testing follow a staged counseling protocol modeled on Huntington's disease — pre-test counseling, a deliberate interval, result disclosure with support, and follow-up. That protocol exists because the result is unmodifiable and the disease is currently untreatable at the cause. A clinician who declines to order the panel at a first visit is usually following it, not dismissing you.
Coverage: what insurers will and will not pay for
Coverage turns almost entirely on documented family history, not on the patient's request. Blue Cross Blue Shield of North Carolina's commercial policy covers familial Alzheimer's testing only for people with a family history of autosomal dominant dementia, or a first-degree relative with a known PSEN1, PSEN2 or APP variant. The pedigree is the gate. Other plans go further and refuse outright. Blue Cross Blue Shield of Michigan's medical policy 76764 classifies genetic testing to confirm an Alzheimer's diagnosis or assess risk of developing it — outside reproductive decision-making — as experimental/investigational.
That label means denial, not a higher copay, and it is not appealable on cost grounds alone. Excellus BlueCross BlueShield's policy on lab testing for Alzheimer's disease requires that testing occur in the context of genetic counseling. Booking the counselor is therefore often a precondition of payment rather than an optional add-on — which is another reason self-ordering a panel first can leave you paying for it twice. The one APOE indication payers do reliably cover is pre-treatment genotyping. The FDA prescribing information for Leqembi (lecanemab) directs that ApoE ε4 status be determined before starting treatment, because symptomatic ARIA-E — brain swelling — occurred in 9% of ε4 homozygotes versus 2% of heterozygotes and 1% of non-carriers. That is testing to dose a drug safely, which is a different question from predicting risk.
What it costs if you pay yourself
Prices split sharply between the single-gene risk test and the multigene panel: The absence of a published panel price is itself worth noting. You cannot budget for a familial panel the way you can price a cholesterol test, and a denied prior authorization can leave the full amount with you. Ask the lab for a written self-pay quote and the specific CPT codes before anyone draws blood.
- Self-pay APOE genotyping: listed at $184.99 lab-direct, per the TestWell APOE cost guide.
- APOE through a neurology or genetics clinic: roughly $300–$600, including counseling.
- Multigene dementia panels: no published list price. Fulgent Genetics' 16-gene Alzheimer/dementia panel says "Call for details."
GINA protects less than most people assume
Federal law covers two situations and leaves out three that matter here. As the National Human Genome Research Institute explains in its page on genetic discrimination, GINA bars genetic discrimination in health insurance and employment — but it does not cover life insurance, disability insurance or long-term-care insurance. Only some states extend protection to those lines.
Long-term-care insurance is precisely the product a person worried about dementia is most likely to want. Testing first and applying later can mean answering a question about known genetic results on an application that is not covered by GINA. The sequencing advice follows from that: if you are considering life, disability or long-term-care coverage, sort that out before testing, and raise the question with a genetic counselor during pre-test counseling. This is one of the concrete things that staged protocol is designed to surface.
How to ask for the right referral
The referral you want is to a memory clinic with genetic counseling available — not to a lab. Guidance for early-onset dementia recommends exactly that, and research in an Amsterdam memory clinic cohort found that conventional clinical selection criteria miss carriers of pathogenic dementia variants.
In other words, not meeting the textbook family-history profile is not proof there is nothing to find, which is an argument for being assessed by people equipped to make that judgment. What to bring to the appointment: Age at onset is the single most informative item on that list. Repeated onset in the forties and fifties across generations is what moves a panel from unindicated to plausibly indicated; a single grandparent diagnosed at 82 does not.
- A written family tree covering at least three generations: who was affected, age at first symptoms, age at death, and the diagnosis each person was actually given.
- Any documentation of a relative's genetic test result — the lab report itself, with the variant named, is far more useful than a recollection that "it was genetic."
- Records of non-Alzheimer's dementias in the family (frontotemporal dementia, ALS, Parkinson's), since several genes span those diagnoses.
- Your insurer's medical policy on familial Alzheimer's testing, printed from their site, so the criteria are on the table at the first conversation.
Frequently Asked Questions
Can I order a familial Alzheimer's panel myself, without a doctor?
Lab-direct APOE genotyping is available self-pay at around $185, but multigene familial panels are quoted on request rather than listed, and insurers that cover testing generally require it be done alongside genetic counseling. Self-ordering can mean paying out of pocket and then repeating the process through the clinic.
If my panel is negative, am I in the clear?
No. The panel covers APP, PSEN1 and PSEN2, which the NIA says account for only 10–15% of early-onset cases, and early-onset is itself under 10% of all Alzheimer's. A negative result rules out those specific causes and says nothing about overall risk.
Why would an insurer pay for APOE testing but not a familial panel?
Because the covered indication is drug safety, not risk prediction. The Leqembi label requires ApoE ε4 status before treatment, since ARIA-E rates rise sharply in ε4 homozygotes.
Should I get tested before applying for long-term-care insurance?
Discuss the order with a genetic counselor first. GINA does not cover long-term-care, life or disability insurance, so a known result can affect those applications in states without additional protection.
